Hyperlipemia
Conditions
Interventions
Rosuvastatin high-dose medication group
Rosuvastatin low-dose medication group
Sponsors
Department of Cardiovascular medicine, Saga University Faculty of Medicine
Edogawa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: he hyperlipemic subject who has not reached a lipid management target in the primary prevention (Category 3) or the secondary prevention patient set by the arteriosclerotic disease prevention guideline (2007)
Exclusion criteria
Exclusion criteria: 1) Patients whom Rosuvastatin has already been prescribed 2) Familial hyperlipidemia or Secondary hyperlipemia 3) Patients with a history of hypersensitivity to statin 4) Patients who showed the symptoms of cerebrovascular disorder within 3months 5) Patients who showed the symptoms of myocardial infarction within 3 months 6) Patients diagnosed active liver disease(ALT or AST > 100 IU/L, T-bil > 2.5 mg/dL) 7) Patients with severe kidney dysfunction and also patients with poor control of kidney dysfunction 8)serum CK > 500 IU/L 9) Patients who are prescribing cyclosporin 10) Pregnant or lactating women 11) Decreased thyroid activity, A hereditary line disease(Muscular dystrophy etc) or patients with the family history, patients with the anamnesis of drug-induced muscle disorder 12) Drug abuse and/or patients of alcoholism 13)Patients who are considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of the inflammation marker at the time of registration and 12 weeks after. (Hs-CRP,RLP-cholesterol,MDA-LDL,small dense LDL,HMW-adioponectin,RAGE) | — |
Secondary
| Measure | Time frame |
|---|---|
| The serum lipid improvement effect of 4 weeks and 12 weeks after. (LDL-cholesterol,TG,HDL-cholesterol, LDL/HDL ratio) | — |
Countries
Japan
Contacts
Public ContactJunichi Oyama
Saga University Faculty of Medicine Department of Cardiovascular medicine
Outcome results
None listed